


# Accepted Manuscript

Phase 3 Study of Reslizumab in Patients with Poorly Controlled Asthma: Effects Across a Broad Range of Eosinophil Counts

Jonathan Corren, MD, Steven Weinstein, MD, Lindsay Janka, James Zangrilli, MD, Margaret Garin, MD



PII: S0012-3692(16)45715-6

DOI: [10.1016/j.chest.2016.03.018](https://doi.org/10.1016/j.chest.2016.03.018)

Reference: CHEST 379

To appear in: *CHEST*

Received Date: 9 October 2015

Revised Date: 17 February 2016

Accepted Date: 11 March 2016

Please cite this article as: Corren J, Weinstein S, Janka L, Zangrilli J, Garin M, Phase 3 Study of Reslizumab in Patients with Poorly Controlled Asthma: Effects Across a Broad Range of Eosinophil Counts, *CHEST* (2016), doi: 10.1016/j.chest.2016.03.018.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

## **Phase 3 Study of Reslizumab in Patients with Poorly Controlled Asthma: Effects Across a Broad Range of Eosinophil Counts**

**Running title:** Phase 3 Trial of Reslizumab for Asthma

*Jonathan Corren, MD; Steven Weinstein, MD; Lindsay Janka; James Zangrilli, MD; Margaret Garin, MD*

**AFFILIATIONS:** From the David Geffen School of Medicine at UCLA (Dr Corren), Los Angeles, CA, USA; Allergy and Asthma Specialists Medical Group and Research Center (Dr Weinstein), Huntington Beach, CA, USA; Teva Pharmaceuticals Inc (Ms Janka, Dr Zangrilli, Dr Garin), Frazer, PA, USA

**PRIOR PRESENTATION:** This study was previously presented, in part, at the European Respiratory Society International Congress, Munich, Germany (September 6–10, 2014).

**FUNDING:** The study was funded by Teva Branded Pharmaceutical Products R&D, Inc.

**CORRESPONDENCE TO:** Jonathan Corren, MD, 10780 Santa Monica Blvd., Suite 280, Los Angeles, CA 90025, USA. E-mail: jcorren@ucla.edu

**CONFLICT OF INTEREST:** Dr Corren has been involved in speaker bureau activities for Genentech and Merck and has served on advisory boards for Vectura Pharmaceuticals, Genentech, Novartis and Merck. Dr Weinstein has received research grants from AstraZeneca, and was involved in speaker bureau activities and advisory boards for Teva; these activities were outside of the submitted work. Ms Lindsay Janka and Dr Garin are employees of Teva and have shareholdings in Teva. Dr Zangrilli is an

Download English Version:

<https://daneshyari.com/en/article/5600656>

Download Persian Version:

<https://daneshyari.com/article/5600656>

[Daneshyari.com](https://daneshyari.com)